New Cervical Cancer Screening Guidelines: Rationale and Addressing Barriers to Adoption - Available to ARHP Members Only
This is an internet-based activity that should take one hour to complete. To receive continuing education credit, learners should 1) take the pre-test 2) review the webinar and 3) complete the post-test.
At the conclusion of this presentation, participants should be able to:
- Discuss the epidemiology and natural history of HPV infection and cervical intraepithelial neoplasia
- Identify the most common genital HPV types in benign and malignant disease
- Discuss the significance of persistent infection with high-risk HPV type
- Identify the most common mode of HPV transmission
- Discuss the 2012 Cervical Cancer Screening Guidelines
- Discuss barriers to adoption of the guidelines
Physicians: The Association of Reproductive Health Professionals is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ARHP designates this internet enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Others: A certificate of attendance will be issued indicating that this activity is accredited for 1 hour of AMA PRA Category 1 CreditTM.
This program is sponsored by the Association of Reproductive Health Professionals.
This webinar is funded by ARHP member dues.
The intended audiences for this activity are women’s health and primary care providers, including physicians, nurse practitioners, nurse-midwives, pharmacists, physician assistants, and other professionals who work in obstetrics/gynecology, family medicine, internal medicine, and related fields.
All individuals in a position to influence the content of this activity must disclose relevant financial relationship(s) with commercial interests and the nature of the relationship. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients.
- Barbara J.B. Clark, MPAS, PA-C (Planner) – Speaker for Ortho Women’s Health and Urology and Wyeth Pharmaceuticals
- Nancy R. Berman MSN, ANP-BC, NCMP (Faculty/Speaker) – Speaker for QIAGEN, Amgen, and Merck and Co., Inc.; and a member of LabCorp’s Clinical Advisory Board for Women’s Health
- Richard Guido, MD (Planner) – Conducted research for Graceway Pharmaceuticals and Tigress Pharmaceuticals; speaker for Merck and Co., Inc.; consultant for GlaxoSmithKline
- Mary Rubin, RNC, PhD, CRNP (Planner) – Speaker for Digene Corporation and Merck and Co., Inc.
- Marie Savard, MD (Planner) – Speaker for Digene Corporation and GlaxoSmithKline
- Maria Trent, MD (Planner) – Speaker for Merck and Co., Inc.
- Thomas C. Wright, MD (Planner) – Consultant for Glaxo Smith Kline, Merck and Co., Inc. and Roche Molecular Systems, Inc.
- Don Downing, RPh (Planner), Francisco Garcia, MD, MPH (Planner), Sherri Sheinfeld Gorin, PhD (Planner), Julie Hibben, LMSW, CPSI (Planner), Anafidelia Tavares, MD(Planner), Camille Harris, MPH (ARHP Program Manager), Beth Jordan Mynett, MD (ARHP Medical Director), Diane Shannon, MD, MPH (Consulting Writer),Amy Swann, MA (ARHP Vice President) have nothing to disclose